ArticleVaccine2010
Effective induction of protective systemic immunity with nasally administered vaccines adjuvanted with IL-1.
Article in Vaccine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 37 citations in OpenAlex.
- A novel cross-species vaccine design and nasal immunization strategy based on recombinantApplied and environmental microbiology · 2026Article
- Article
- Nasal Immunization With Small Molecule Mast Cell Activators Enhance Immunity to Co-Administered Subunit Immunogens.Frontiers in immunology · 2021Article
- Nasal vaccination of β7 integrin-deficient mice retains elevated IgA immunity.Immunology and cell biology · 2020Article
- Enhancing the Immune Response of a Nicotine Vaccine with Synthetic Small "Non-Natural" Peptides.Molecules (Basel, Switzerland) · 2020Article
- Optimized Mucosal Modified Vaccinia Virus Ankara Prime/Soluble gp120 Boost HIV Vaccination Regimen Induces Antibody Responses Similar to Those of an Intramuscular Regimen.Journal of virology · 2019Article
- Article
- Modified Vaccinia Ankara Virus Vaccination Provides Long-Term Protection against Nasal Rabbitpox Virus Challenge.Clinical and vaccine immunology : CVI · 2016Article
- Structure and function of chicken interleukin-1 beta mutants: uncoupling of receptor binding and in vivo biological activity.Scientific reports · 2016Article
- Innate endogenous adjuvants prime to desirable immune responses via mucosal routes.Protein & cell · 2015Review
- Enhancement of nasal HIV vaccination with adenoviral vector-based nanocomplexes using mucoadhesive and DC-targeting adjuvants.Pharmaceutical research · 2014Article
- Intranasal mRNA nanoparticle vaccination induces prophylactic and therapeutic anti-tumor immunity.Scientific reports · 2014Article
- Retention of structure, antigenicity, and biological function of pneumococcal surface protein A (PspA) released from polyanhydride nanoparticles.Acta biomaterialia · 2013Article
- Article
- Maximal adjuvant activity of nasally delivered IL-1α requires adjuvant-responsive CD11c(+) cells and does not correlate with adjuvant-induced in vivo cytokine production.Journal of immunology (Baltimore, Md. : 1950) · 2012Article
- Transferrin conjugation confers mucosal molecular targeting to a model HIV-1 trimeric gp140 vaccine antigen.Journal of controlled release : official journal of the Controlled Release Society · 2012Article
- Stable dry powder formulation for nasal delivery of anthrax vaccine.Journal of pharmaceutical sciences · 2012Article
- Article
- Cytokines: the future of intranasal vaccine adjuvants.Clinical & developmental immunology · 2011Review
- Vaccines for gonorrhea: can we rise to the challenge?Frontiers in microbiology · 2011Article
Corrections and comments
- Erratum issued
Authors and funding
14 authors at 4 institutions in 1 country.
Funding
Abstract
IL-1α and IL-1β were evaluated for their ability to provide adjuvant activity for the induction of serum antibody responses when nasally administered with protein antigens in mice and rabbits. In mice, intranasal (i.n.) immunization with pneumococcal surface protein A (PspA) or tetanus toxoid (TT) combined with IL-1β induced protective immunity that was equivalent to that induced by parenteral immunization. Nasal immunization of awake (i.e., not anesthetized) rabbits with IL-1-adjuvanted vaccines induced highly variable serum antibody responses and was not as effective as parenteral immunization for the induction of antigen-specific serum IgG. However, i.n. immunization of deeply anesthetized rabbits with rPA+IL-1α consistently induced rPA-specific serum IgG ELISA titers that were not significantly different than those induced by intramuscular (IM) immunization with rPA+alum although lethal toxin-neutralizing titers induced by nasal immunization were lower than those induced by IM immunization. Gamma scintigraphy demonstrated that the enhanced immunogenicity of nasal immunization in anesthetized rabbits correlated with an increased nasal retention of i.n. delivered non-permeable radio-labeled colloidal particles. Our results demonstrate that, in mice, IL-1 is an effective adjuvant for nasally administered vaccines for the induction of protective systemic immunity and that in non-rodent species, effective induction of systemic immunity with nasally administered vaccines may require formulations that ensure adequate retention of the vaccine within the nasal cavity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.